Patents by Inventor Bennett C. Laguzza

Bennett C. Laguzza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytotoxic drug conjugates
    Patent number: 5144012
    Abstract: Conjugates of antibodies and cytotoxic methotrexate drugs make use of liners between the drug and antibody which are simple organic groups, wherein the link to the antibody is an acyl group and the link to the drug is an alkylidene hydrazide.
    Type: Grant
    Filed: February 15, 1991
    Date of Patent: September 1, 1992
    Assignee: Eli Lilly and Company
    Inventors: David A. Johnson, Bennett C. Laguzza, William L. Scott
  • Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
    Patent number: 5094849
    Abstract: A series of antibody-vinca drug conjugates comprise antibodies which target antigens associated with undesirable cells, so that the cells are controlled or killed by the cytotoxic vinca drug. The drug is linked to the antibody through an organic group comprising a carbonyl at the antibody end, and an alkylidene hydrazide at the vinca end.
    Type: Grant
    Filed: January 14, 1991
    Date of Patent: March 10, 1992
    Assignee: Eli Lilly and Company
    Inventors: George J. Cullinan, Bennett C. Laguzza, William L. Scott
  • Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
    Patent number: 5028697
    Abstract: Conjugates of antibodies and cytotoxic methotrexate drugs make use of linkers between the drug and antibody which are simple organic groups, wherein the link to the antibody is an acyl group and the link to the drug is an alkylidene hydrazide.
    Type: Grant
    Filed: August 8, 1988
    Date of Patent: July 2, 1991
    Assignee: Eli Lilly and Company
    Inventors: David A. Johnson, Bennett C. Laguzza, William L. Scott
  • Intermediates for antibody-vinca drug conjugates
    Patent number: 5006652
    Abstract: A seris of antibody-vinca drug conjugates comprise antibodies which target antigens associated with undesirable cells, so that the cells are controlled or killed by the cytotoxic vinca drug. The drug is linked to the antibody through an organic group comprising a carbonyl at the antibody end, and an alkylidene hydrazide at the vinca end.
    Type: Grant
    Filed: August 8, 1988
    Date of Patent: April 9, 1991
    Assignee: Eli Lilly and Company
    Inventors: George J. Cullinan, Bennett C. Laguzza, William L. Scott
  • Hydrazone immunoglobulin conjugates
    Patent number: 4801688
    Abstract: Immunoglobulin conjugates formed by reaction of an antineoplastic indole-dihydroindole vinca alkaloid containing a hydrazine group attached at C-3 or C-4 with an oxidized glycoprotein containing aldehyde groups.
    Type: Grant
    Filed: October 7, 1987
    Date of Patent: January 31, 1989
    Assignee: Eli Lilly and Company
    Inventors: Bennett C. Laguzza, Cynthia L. Nichols
  • 2-Alkyl(or phenyl)thio-6-n-alkylergolines are dopamine D-1 antagonists without D-2 agonist activity
    Patent number: 4801712
    Abstract: D-2-Alkyl(or phenyl)thio-6-n-alkylergolines or .+-.-2-alkyl(or phenyl)thio-4-dialkylaminotetrahydrobenz[c,d]indoles, dopamine D-1 antagonists.
    Type: Grant
    Filed: June 11, 1987
    Date of Patent: January 31, 1989
    Assignee: Eli Lilly and Company
    Inventors: Bennett C. Laguzza, Cynthia L. Nichols, Nicholas J. Bach
  • 2-alkyl(or phenyl)thio-6-N alkyl ergolines and 4-dialkylaminotetrahydrobenz[c,d]indoles
    Patent number: 4683313
    Abstract: D-2-Alkyl(or phenyl)thio-6-n-alkylergolines or .+-.-2-alkyl(or phenyl)thio-4-dialkylaminotetrahydrobenz[c,d]indoles, dopamine D-1 antagonists.
    Type: Grant
    Filed: June 24, 1985
    Date of Patent: July 28, 1987
    Assignee: Eli Lilly and Company
    Inventors: Bennett C. Laguzza, Cynthia L. Nichols, Nicholas J. Bach
  • 1-Substituted-6-n-propyl-8.beta.-methylthio-methylergolines
    Patent number: 4675322
    Abstract: N-1-substituted-6-n-propyl-8.beta.-methylthio-methylergoline, D-2 agonists without interaction with alpha adrenergic receptors.
    Type: Grant
    Filed: December 10, 1984
    Date of Patent: June 23, 1987
    Assignee: Eli Lilly and Company
    Inventor: Bennett C. Laguzza
  • Dialkylaminotetrahydroquinazoline
    Patent number: 4622398
    Abstract: 2-Permissibly-substituted-6-dialkylaminotetrahydroquinazolines, receptor agonists.
    Type: Grant
    Filed: June 24, 1985
    Date of Patent: November 11, 1986
    Assignee: Eli Lilly and Company
    Inventor: Bennett C. Laguzza